Call Text Chat Email Refer a Patient Join a Study

Search

MotherToBaby

Medications and More during pregnancy and breastfeeding

Lurasidone (Latuda®)

Selected References:

  • Campbell LS, et al. 2025. Balancing Mental Health and Breastfeeding: Evaluating the Transfer of Lurasidone Into Human Milk. J Clin Psychiatry; 86(4):25m15955. 
  • Cohen LS, et al. 2023. Reproductive safety of lurasidone and quetiapine: Update from the National Pregnancy Registry for Psychiatric Medications. J Womens Health (Larchmt); 32(4):452-462.  
  • Cruz MP. 2011. Lurasidone HCl (Latuda), an oral, once-daily atypical antipsychotic agent for the treatment of patients with schizophrenia. P & T: a peer-reviewed journal for formulary management; 36(8):489–492. 
  • Damkier, P & Videbech, P. 2018. The safety of second-generation antipsychotics during pregnancy: A clinically focused review. CNS Drugs; 32:351–366. 
  • FDA. 2011. FDA Drug Safety Communication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. Previously retrieved from  http://www.fda.gov/Drugs/DrugSafety/ucm243903.htm.  
  • Greenberg WM & Citrome L. 2017. Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a second-generation antipsychotic: a systematic review of the published literature. Clin Pharmacokinet; 56:493–503. 
  • Kantrowitz JT, Citrome L. 2012. Lurasidone for schizophrenia: what’s different? Expert Rev Neurother; 12(3):265-73.  
  • Keightley P, et al. 2020. Lurasidone in lactation: A case study with laboratory and clinical outcomes. Aust N Z J Psychiatry; 54:1035–1036. 
  • Kernizan N, et al. 2024. Mood stabilizers for treatment of bipolar disorder in pregnancy and impact on neonatal outcomes. Bipolar Disord; 26(8):779-784.  
  • Kernizan N, et al. 2025. Prescribing Patterns for the Treatment of Bipolar Disorder in Pregnancy: A Retrospective Cohort Study. J Clin Med; 14(5):1638.  
  • Luo Z, et al. 2025. The safety analysis of lurasidone based on the real-world data of FAERS database. Expert Opin Drug Saf; 1-11.  
  • Montiel C, et al. 2022. Perinatal use of lurasidone for the treatment of bipolar disorder. Exp Clin Psychopharmacol; 30(2):249-252.  
  • Sumitomo Pharma America, Inc. (Last updated 2025). Latuda drug label. Source: National Library of Medicine. Available at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afad3051-9df2-4c54-9684-e8262a133af8.  
  • Terrana N, et al. 2015. Pregnancy outcomes following in utero exposure to second-generation antipsychotics: A systematic review and meta-analysis. Journal of Clinical Psychopharmacology; 35(5):559–565.  
  • Viguera AC, et al. 2022. Breastfeeding practices among women taking second-generation antipsychotics: Findings from the National Pregnancy Registry for Atypical Antipsychotics. Arch Womens Ment Health; 25:511–6.  
  • Wang E, et al. 2025. Comparative Safety of Antipsychotic Medications and Mood Stabilizers During Pregnancy: A Systematic Review and Network Meta-analysis of Congenital Malformations and Prenatal Outcomes. CNS Drugs; 39(1):1-22.  

 

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $1,200,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.